Meihua International Medical Technologies Co Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Meihua International Medical Technologies Co Ltd (MHUA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Meihua International Medical Technologies Co Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 62M vs 180,643M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs holding steady (-0.2%) for its tracked peer group.
- Profitability: Its 11.0% net margin compares with 7.6% for the peer group.
- Peer revenue share: Meihua International Medical Technologies Co Ltd accounted for 0.1% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.05M compares with $0.37M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MHUA Sales vs. its Competitors, Q4 2025
With a net margin of 10.98 %, Meihua International Medical Technologies Co Ltd achieved higher profitability than its competitors (7.55 %).
Meihua International Medical Technologies Co Ltd generated 0.14 % of the combined sales of its peer group.
Meihua International Medical Technologies Co Ltd vs. its Competitors, Q4 2025
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Meihua International Medical Technologies Co Ltd and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Meihua International Medical Technologies Co Ltd | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Meihua International Medical Technologies Co Ltd's competitor groups requires a Commercial License.
Meihua International Medical Technologies Co Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Meihua International Medical Technologies Co Ltd | Yes | No | No | Yes |
| Competitors combined (37) | ||||
| Similar Growth & Profitability (8) | 62.50 % (5 of 8) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MHUA Stock Performance relative to its Competitors
MHUA Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Axogen inc | 282.9% | Outperformed |
| 2 | Orchestra Biomed Holdings Inc | 282.9% | Outperformed |
| 3 | Atricure Inc | 282.9% | Outperformed |
| 4 | Angiodynamics Inc | 282.9% | Outperformed |
| 5 | Livanova Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Meihua International Medical Technologies Co Ltd's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Meihua International Medical Technologies Co Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Meihua International Medical Technologies Co Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Meihua International Medical Technologies Co Ltd | 2.86 | 61.79 |
| Abbott Laboratories | 176,419.43 | 45,134.00 |
| Medtronic Plc | 115,016.45 | 37,542.00 |
| Stryker Corp | 106,269.66 | 25,837.00 |
| Boston Scientific Corporation | 65,053.43 | 20,997.00 |
| Becton Dickinson And Company | 50,582.30 | 20,840.00 |
| SUBTOTAL | 643,861.71 | 182,633.71 |
Sign in to see all competitors of Meihua International Medical Technologies Co Ltd.
Sources: Meihua International Medical Technologies Co Ltd's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Meihua International Medical Technologies Co Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Meihua International Medical Technologies Co Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Abbott Laboratories | Diabetes Care 17.78 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 55.02 % |
| Boston Scientific Corporation | Cardiovascular 67.31 % |
| Becton Dickinson And Company | Medical Essentials 34.94 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Meihua International Medical Technologies Co Ltd.
Meihua International Medical Technologies Co Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Meihua International Medical Technologies Co Ltd | 3 | 52,904 | 5,806 |
| Abbott Laboratories | 176,419 | 392,470 | 54,574 |
| Medtronic Plc | 115,016 | 395,179 | 55,463 |
| Stryker Corp | 106,270 | 461,375 | 66,589 |
| Boston Scientific Corporation | 65,053 | 355,881 | 62,186 |
| Becton Dickinson And Company | 50,582 | 289,444 | 13,069 |
| PEERS TOTAL | 643,859 | 366,011 | 38,878 |
Sign in to see all peers for Meihua International Medical Technologies Co Ltd.
Meihua International Medical Technologies Co Ltd's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Abbott Laboratories | Non-US 61.62 % |
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.26 % |
| Boston Scientific Corporation | United States 63.11 % |
| Becton Dickinson And Company | United States 61.88 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Meihua International Medical Technologies Co Ltd.
Meihua International Medical Technologies Co Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 222 companies in Meihua International Medical Technologies Co Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Meihua International Medical Technologies Co Ltd ranks #0 of 222 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 587, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 145,832 | 13.38 % |
| 2 | Medtronic Plc | 113,372 | 10.40 % |
| 3 | Stryker Corp | 105,405 | 9.67 % |
| 4 | 3m Company | 88,542 | 8.12 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Becton Dickinson And Company | 1,234 | 5.2% |
| 7 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 8 | Dexcom Inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Alcon inc | 1,234 | 5.2% |
| 0 | Meihua International Medical Technologies Co Ltd | 3 | 0.00 % |
Market cap and industry share for the rest of Meihua International Medical Technologies Co Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-12-08.
Meihua International Medical Technologies Co Ltd's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (288 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 31.01 % | 53.35 % (avg) | -22.3 pp |
| Operating Margin | 13.41 % | industry median | +23.3 pp |
| EBITDA Margin | 16.11 % | -6.82 % (avg) | +22.9 pp |
| Capital Intensity (Capex / Revenue) | 0.03 % | 5.43 % (avg) | -5.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Meihua International Medical Technologies Co Ltd's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (288 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 1.4x | 34.6x | -33.2x |
| EV / EBITDA | 0.3x | 19.7x | -19.3x |
| P/B | 0.0x | 4.7x | -4.7x |
| Return on Equity | 3.59 % | industry aggregate | -4.84 % |
| Return on Invested Capital | 2.19 % | -2.32 % (avg) | 4.51 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Meihua International Medical Technologies Co Ltd's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | -6.05 % | -0.19 % | -36.24 % |
| Operating Margin | 15.11 % | 14.77 % | 13.41 % |
| Return on Invested Capital | 4.99 % | 4.44 % | 2.19 % |
| P/E | 3.8x | 1.6x | 1.4x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Meihua International Medical Technologies Co Ltd's Strategic Group Map
Every company in Meihua International Medical Technologies Co Ltd's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Meihua International Medical Technologies Co Ltd is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Meihua International Medical Technologies Co Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 587 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.03 % vs industry average 5.43 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Meihua International Medical Technologies Co Ltd's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Meihua International Medical Technologies Co Ltd's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Meihua International Medical Technologies Co Ltd's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Meihua International Medical Technologies Co Ltd falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Meihua International Medical Technologies Co Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 23.3 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Trades at a lower P/E than the industry average (1.4x vs 34.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Meihua International Medical Technologies Co Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Meihua International Medical Technologies Co Ltd | 0.83 | 8.42 | 0.05 |
| Abbott Laboratories | 0.47 | 1.60 | 0.35 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.48 | 1.99 | 0.68 |
| Boston Scientific Corporation | 0.25 | 1.54 | 0.47 |
| Becton Dickinson And Company | 0.10 | 1.00 | 0.73 |
Sign in to see all peers for Meihua International Medical Technologies Co Ltd.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Meihua International Medical Technologies Co Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Meihua International Medical Technologies Co Ltd | Q4 2025 | -36.2 % | -37.4 % |
| Abbott Laboratories | Q1 2026 | +7.8 % | -18.7 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q2 2026 | +9.4 % | +44.3 % |
| Boston Scientific Corporation | Q2 2026 | +7.5 % | +13.8 % |
| Becton Dickinson And Company | Q2 2026 | +5.4 % | -34.3 % |
| PEERS TOTAL | +8.7 % | +21.1 % |
Sign in to see all peers for Meihua International Medical Technologies Co Ltd.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Meihua International Medical Technologies Co Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Meihua International Medical Technologies Co Ltd | Q4 2025 | -36.4 % | -88.3 % |
| Abbott Laboratories | Q1 2026 | +9.4 % | -17.6 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q2 2026 | -4.1 % | +10.4 % |
| Boston Scientific Corporation | Q2 2026 | -2.6 % | +24.2 % |
| Becton Dickinson And Company | Q2 2026 | +7.1 % | -12.8 % |
Sign in to see all peers for Meihua International Medical Technologies Co Ltd.
Meihua International Medical Technologies Co Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Meihua International Medical Technologies Co Ltd | 3.27% | 3.59% | 3.59% |
| Abbott Laboratories | 6.87% | 8.15% | 12.09% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.89% | 8.80% | 16.36% |
| Boston Scientific Corporation | 8.34% | 9.91% | 14.77% |
| Becton Dickinson And Company | 1.77% | 2.22% | 3.79% |
Sign in to see all peers for Meihua International Medical Technologies Co Ltd.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Meihua International Medical Technologies Co Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Meihua International Medical Technologies Co Ltd | 0.42 | 0.05 |
| Abbott Laboratories | 28.13 | 3.91 |
| Medtronic Plc | 263.24 | 3.06 |
| Stryker Corp | 28.53 | 4.11 |
| Boston Scientific Corporation | 17.88 | 3.10 |
| Becton Dickinson And Company | 55.54 | 2.43 |
| PEERS AVERAGE | 33.19 | 3.53 |
Sign in to see all peers for Meihua International Medical Technologies Co Ltd.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.